Xavier Fradera
0000-0002-6118-075X
Merck
5 papers found
Refreshing results…
Oxetane Promise Delivered: Discovery of Long-Acting IDO1 Inhibitors Suitable for Q3W Oral or Parenteral Dosing
Utilization of Metabolite Identification and Structural Data to Guide Design of Low-Dose IDO1 Inhibitors
Carbamate and N-Pyrimidine Mitigate Amide Hydrolysis: Structure-Based Drug Design of Tetrahydroquinoline IDO1 Inhibitors
Discovery of Potent and Orally Available Bicyclo[1.1.1]pentane-derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors
Discovery of Amino-cyclobutarene-derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors for Cancer Immunotherapy
Missing publications? Search for publications with a matching author name.